



Final Appraisal Recommendation

Advice No: 3416 – November 2016

Dequalinium chloride (Fluomizin®) 10 mg vaginal tablets

Submission by Kora Healthcare

Recommendation of AWMSG

Dequalinium chloride (Fluomizin®) for the treatment of bacterial vaginosis is recommended as an option for restricted use within NHS Wales.

Dequalinium chloride (Fluomizin®) for the treatment of bacterial vaginosis is restricted for use after initial treatment is ineffective or not tolerated as an alternative option to clindamycin vaginal cream.

Dequalinium chloride (Fluomizin®) is not recommended for use within NHS Wales outside of this population.

Additional note(s):

- The company provided clinical and cost-effectiveness evidence for dequalinium chloride compared to clindamycin only.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2775), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Kora Healthcare
Date of first issue	November 2016
Last reviewed	August 2020

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3416:
Dequalinium chloride (Fluomizin®) 10 mg vaginal tablets. November 2016.